Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy.

TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway. Oncotarget (2016) 0.79

A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci (2016) 0.77

"TRIMing" the patient population to increase the benefit of mTOR inhibition. J Natl Cancer Inst (2014) 0.77

TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling. Int J Mol Sci (2017) 0.75

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (2010) 25.32

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51

Cancer genes and the pathways they control. Nat Med (2004) 24.22

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol (2009) 21.94

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52

Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46

REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85

TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol (2008) 4.21

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62

RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27

TRIM proteins and cancer. Nat Rev Cancer (2011) 2.84

Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev (2010) 2.54

Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ (2013) 2.31

Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med (2013) 2.23

Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol (1995) 2.03

The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res (2002) 1.60

A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology (2010) 1.43

Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33

Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer (2007) 1.24

Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol (2013) 1.06

A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut (2012) 1.05

Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth. Cancer Res (2007) 1.03

Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma. Cancer Sci (2012) 0.88

Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett esophagus. Am J Clin Pathol (2001) 0.86